Health Canada has approved Miacalcin NS, the first nasal spray treatment for osteoporotic women, at least five years into their menopause. And because it is administered nasally, Miacalcin NS is absorbed quickly into the bloodstream. Osteoporosis has crippling financial and quality of life consequences on Canadians. Canadian women should consider Miacalcin NS as an important advance in the ongoing battle against osteoporosis. In clinical trials with Miacalcin NS, the overall incidence of side-effects was comparable to placebo.
Bone mass revolves around a phenomenon called remodeling.
Remodeling consists of breaking down small parts of the bones and reforming them. The depletion of estrogen during menopause reduces osteoblast activity, resulting in the escalation of osteoporosis. However, Miacalcin NS inhibits osteoclast activity, thereby reducing bone loss. Among the leading causes of osteoporosis is a great abyss in awareness about the disease that affects about 1 million Canadian women. For example, a 1998 survey of 514 adult American women conducted by Opinion Research International found that only 28 percent knew that women over age 50 were more likely to get osteoporosis than breast cancer, heart disease or Alzheimer's disease.